WeSana Health
WeSana Health is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
WeSana Health is a technology company.
WeSana Health is an emerging life sciences company developing psychedelic and naturally-sourced therapies to treat traumatic brain injury (TBI) and related mental health conditions like post-traumatic stress disorder, anxiety, and depression.[1][2][5] It serves patients such as professional athletes, veterans, and victims of domestic abuse through evidence-based formulations, clinical protocols, and partnerships with academic and TBI organizations, addressing neurological and psychological ailments caused by trauma.[1][2] The company has raised over C$20 million in financing from notable backers like Mike Tyson and George Steinbrenner IV, pursued FDA Investigational New Drug filings for TBI and migraines, and filed two patent applications, signaling strong growth momentum in psychedelic biotechnology.[1][5]
WeSana Health, founded in 2020 and based in Chicago, Illinois, evolved from Made Holding Co. and focuses on psychedelic therapies for brain health.[2][5] Key leadership includes CEO Daniel Novitzky, who transitioned from discussing brain health benefits of psychedelics with scientists to founding the company; Chief Science Officer Mark Wingertzahn, PhD, with experience at GSK, Pfizer, and NYU; and Chief Medical Officer Stephan Bart, MD, who has led over 400 clinical trials.[1] The idea emerged from recognizing psychedelics' potential for TBI, despite stigma, leading to early traction via partnerships, patent filings on November 30, 2021, for neurological treatments, and substantial financing closure.[1][5]
WeSana Health rides the surging psychedelic therapy trend in biotechnology, targeting unmet needs in nervous system diseases amid growing acceptance of psychedelics for mental health post-COVID trauma spikes.[1][3][4] Timing aligns with regulatory shifts, like FDA interest in breakthrough therapies for TBI—a market underserved by traditional drugs—fueled by academic partnerships and psilocybin research momentum.[1] It influences the ecosystem by pioneering athlete/veteran-focused trials, reducing stigma (e.g., via cannabis parallels), and competing with firms like MindMed in drug discovery for brain health, potentially accelerating psychedelic adoption in healthcare.[1][5]
WeSana Health is poised for clinical trial advancements, with IND decisions and Phase 1 data potentially unlocking FDA accelerated paths by 2026, expanding its TBI/migraine pipeline amid rising psychedelic investment.[1][5] Trends like biotech deregulation, veteran mental health funding, and AI-aided drug discovery will shape growth, evolving its role from startup to ecosystem leader in trauma therapies. This positions it to transform brain injury care, building on its mission to deliver evidence-based relief where conventional treatments fall short.[1][2]